AU7349496A - Method for treatment of SLE - Google Patents

Method for treatment of SLE

Info

Publication number
AU7349496A
AU7349496A AU73494/96A AU7349496A AU7349496A AU 7349496 A AU7349496 A AU 7349496A AU 73494/96 A AU73494/96 A AU 73494/96A AU 7349496 A AU7349496 A AU 7349496A AU 7349496 A AU7349496 A AU 7349496A
Authority
AU
Australia
Prior art keywords
sle
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73494/96A
Inventor
Morris Reichlin
Kensei Tsuzaka
Wei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of AU7349496A publication Critical patent/AU7349496A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU73494/96A 1995-05-25 1996-05-24 Method for treatment of SLE Abandoned AU7349496A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45018895A 1995-05-25 1995-05-25
US450188 1995-05-25
US011867 1996-02-15
US1186796P 1996-02-16 1996-02-16
PCT/US1996/007597 WO1996037225A1 (en) 1995-05-25 1996-05-24 Method for treatment of sle

Publications (1)

Publication Number Publication Date
AU7349496A true AU7349496A (en) 1996-12-11

Family

ID=26682878

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73494/96A Abandoned AU7349496A (en) 1995-05-25 1996-05-24 Method for treatment of SLE

Country Status (2)

Country Link
AU (1) AU7349496A (en)
WO (1) WO1996037225A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US7273613B1 (en) 1997-01-13 2007-09-25 The Board of Regents, The University of Oklahoma Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692416A (en) * 1982-12-03 1987-09-08 Yeshiva University Monoclonal antibodies reactive with shared idiotypes on human antibodies to native DNA from patients with systemic lupus erythematosus
WO1994021669A1 (en) * 1993-03-18 1994-09-29 Medclone, Inc. Antigen related to inflammatory diseases

Also Published As

Publication number Publication date
WO1996037225A1 (en) 1996-11-28

Similar Documents

Publication Publication Date Title
AUPN271295A0 (en) Method of treatment
EP0831924A4 (en) Method of treatment for asthma
AU4918796A (en) Methods of treating or preventing psychiatric disorders
AU4958096A (en) Process for the treatment of gases
AU3155495A (en) Method of treating contact lenses
AU1074397A (en) Method for treating anxiety
AU5737996A (en) Method of reducing malodor
AU4901896A (en) Method for treating multiple sclerosis
AU1020997A (en) Method of treating sepsis
AU5198898A (en) Method for treatment of glutamate related disorders
AU7726396A (en) Method for treating anxiety
AU7674796A (en) Method for treating anxiety
AU5713196A (en) Method for treatment of pain
AU4703896A (en) Method for treating multiple sclerosis
AU1710095A (en) Method for isolating of wheyproteins
AU4027097A (en) Method of treatment
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU7349496A (en) Method for treatment of SLE
AU2874497A (en) Balanites aegyptiaca method of treatment
GB9507825D0 (en) Method of treatment
AU5676496A (en) Method of treating endotoxic shock
AU3779595A (en) Method of treating turf
AU3989995A (en) Method of treating membranes
AU7658098A (en) Method for treatment of an article
AU1829695A (en) Method of treatment of talc